Showing 176–200 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Sarah E. Smith-Jeffcoat, MPH, J. P. Cegielski, MD, MPH
…idal activity (EBA) study methodology. Patients at risk for drug-resistant TB will be screened for INH resistance using approved molecular assays. In those with INH-resistant TB, the investigators will quickly perform phenotypic DSTs using the direct method in the Bactec Mycobact…
Michele L Pearson, MD, Sara J Whitehead, MD
…lthcare facilities has been intensified by the emergence of drug-resistant TB strains, including extensively resistant TB strains, and the high mortality of these strains in people living with human immunodeficiency virus (HIV). Healthcare workers are at higher risk of both TB i…
Sema Aytaç, PhD
…ht under control with effective treatment by regular use of drugs. In addition, the symptoms of the patients are relieved until they recover. However, the fatigue of the patients may continue. The disease may continue. In addition to having an effect, fatigue may also occur due t…
Dmytro Butov, MD
Treatment of multidrug-resistant TB (MDR-TB) is 100 times more expensive than treatment of drug-susceptible TB, requiring intensive clinical management for prolonged time (18-24 months) and more toxic treatment course. In prior open label study the investigators have shown that a…
Beverley Stringer
…RO is a sub-study of a TB-PRACTECAL clinical trial for multidrug resistant Tuberculosis. It evaluates the effectiveness of TB-PRACTECAL interventions from the patient perspective in terms of their quality of life, shared decision making and satisfaction with services. Tolerabili…
Sedona Sweeny
…omes and costs of treating MDR-TB are greater than treating drug susceptible TB, both in terms of health service and patient-incurred costs. Urgent action is needed to Identify short, effective and tolerable treatments for people with MDR-TB. The PRACTECAL economic evaluation sub…
Clifton E Barry, Ph.D.
…* Some of the exposed participants may have been exposed to drug-resistant TB. These participants will receive the drug isoniazid to take on a regular schedule to help prevent the latent TB from becoming active TB. The efficacy of treating tuberculin skin test (TST) positive, or…
Christian Lienhardt, MD
The use of fixed-dose combined (FDC) drugs in the treatment of tuberculosis by National Tuberculosis Programmes has been recommended by both the International Union Against Tuberculosis and Lung Disease (The Union) and the World Health Organisation. The advantages of FDC drugs in…
Cristina Vilaplana, MD, PhD
… study is to assess the efficacy and safety of 2 repurposed drugs (acetylsalicylic acid and ibuprofen), for use as adjunct therapy added to, and compared with, the standard of care (SoC) WHO-recommended TB regimen in drug-sensitive (DS) and multi-drug resistant (MDR) TB patients.…
Jeremy M Chakaya, MD, Eveline Klinkenberg, PhD
…many and varied but include fears of expansion of isoniazid resistance and subsequently the development of multi -drug resistant TB with widespread use of IPT. Additionally screening protocols for excluding active TB and selecting persons for IPT have not been uniformly agreed up…
Bern-Thomas Nyang'wa, MD
…omanid in combination with existing and re-purposed anti-TB drugs for the treatment of biologically confirmed pulmonary multi drug-resistant TB (MDR-TB). This is a multi-centre, open label, multi-arm, randomised, controlled, phase II-III trial; evaluating short treatment regimen…
Lorenzo Guglielmetti, Uzma Khan, Gustavo E Velásquez, Maelenn Gouillou, Muhammad Hammad Ali, et al.
**BACKGROUND:** Pre-extensively drug-resistant (pre-XDR) tuberculosis (ie, multidrug-resistant or rifampicin-resistant with additional resistance to any fluoroquinolone) is difficult to treat. endTB-Q aimed to evaluate the efficacy and safety of bedaquiline, delamanid, linezolid,…
Eric Nuermberger, MD
…IV (PLHIV) and high-risk Close Contacts (CC) of adults with Drug Susceptible (DS) or Rifampin Resistant (RR) TB. Treating adult, adolescent, child, and pregnant close contacts (CCs) of drug-sensitive tuberculosis (DS-TB) who are high-risk for developing tuberculosis disease (TBD…
National Institute of Allergy and Infectious Diseases (NIAID)
…s, ages 18-60. Participants will be treated with 4 standard drugs called isoniazid, rifampicin, pyrazinamide and ethambutol. All individuals will take TB medicines for at least 4 months. After 4 months of treatment, if no TB germs are growing in sputum samples, participants will …
Lisa Beth Ferstenberg, M.D.
PNU-100480 is being developed for the treatment of both drug resistant and sensitive tuberculosis. This is an efficacy and safety study to characterize the effect of PNU-100480 when given for 14 days to treatment-naive patients with drug-sensitive pulmonary tuberculosis.
J Shenje, G Maartens, L Moran, Y Cramer, J D L Rios, et al.
…><title>BACKGROUND</title>Bedaquiline and delamanid are key drugs in the treatment of multidrug-resistant TB. It is unclear whether HIV affects the pharmacokinetics of bedaquiline and delamanid.</sec><sec><title>METHODS</title>Participants with multidrug-resistant TB were randomi…
Laura Iavarone, Silvia M Lavezzi, Antonio J Carcas, Tetyana Chaychenko, Raquel Gabarro-Carrion, et al.
New drugs are urgently needed to treat drug-resistant tuberculosis in combination regimens. Ganfeborole demonstrated bactericidal activity and good tolerability in clinical trials. In preclinical studies, ganfeborole showed embryofetal developmental effects, currently mandating h…
Novartis Pharmaceuticals
… Lamprene®/Clofazimine is approved by FDA (the U.S Food and Drug Administration) for the treatment of leprosy. It is no longer available through pharmacies in the US. It is being tested in non-Novartis clinical studies for drug resistant tuberculosis and non-tuberculous mycobacte…
Adam Penn-Nicholson
…ining 6-9 month regimen, and so it is necessary to rule-out resistance to these compounds prior to treating patients with the shorter regimen. Currently there are no WHO endorsed test that can diagnose MTB and identify resistance to both first and second-line drugs in a single as…
Jyoti S. Mathad, MD, MSc
The purpose of this study was to evaluate the pharmacokinetics (PK), tolerability, and safety of once-weekly doses of rifapentine (RPT) and isoniazid (INH) in HIV-1-infected and HIV-1-uninfected pregnant and postpartum women with latent tuberculosis (TB). TB is a major cause of …
Linda J Harrison, Gustavo E Velásquez, Russell R Kempker, Marjorie Z Imperial, Eric Nuermberger, et al.
**BACKGROUND:** The standard of care (SOC) treatment for drug-susceptible pulmonary tuberculosis (DS-TB) consists of isoniazid, rifampicin, pyrazinamide, and ethambutol (HRZE). New treatment regimen options for DS-TB are needed as HRZE is long in duration (6 months), associa…
Yilin Zhang, Yang Li, Yan Ren, Ting Li, Yajiao Xing, et al.
…fficacy and safety of short-term regimens utilizing various drug combinations is essential across different settings. **METHODS:** INSPIRE TB is a pragmatic, multicentre, randomised, controlled, non-inferiority open-label trial to evaluate novel regimens in pulmonary RR-TB patie…
Olanisun P Adewole, MD, Bolanle A Omotoso, MD
…y contributing to frequent relapses and to the emergence of drug-resistant TB. In addition, individuals who have been clinically cured may have lung damage, which could be permanent. Therefore, new and more effective therapeutic agents against TB are needed. Emerging evidence has…
Valeria C Rolla, PhD, Valeria C Rolla, PhD
…l and virological endpoints throughout the study with these drugs. Some attempts have been made to evaluate the pharmacokinetics of lopinavir using ritonavir as booster by some researchers with dosages of 400/100 and 533/133 mg (the last dosage would be achieved with an addition…
Wenhong Zhang, PhD
…sted of clofazimine for 36\~44 weeks) in subjects with multidrug-resistant tuberculosis (MDR-TB) compared to WHO standardized shorter regimen of 36-44 weeks. The TB-TRUST is a phaseIII, multicenter, open-label, randomized controlled trial. The purpose of this study is to assess …